Manuel Hidalgo Medina-rekin lankidetzan egindako argitalpenak (10)

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

2013

  1. Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 503-508

2012

  1. A comparison of EGFR mutation testing methods in lung carcinoma: Direct sequencing, real-time PCR and immunohistochemistry

    PLoS ONE, Vol. 7, Núm. 8

2003

  1. Progress in the development and acquisition of anticancer agents from marine sources

    Annals of Oncology, Vol. 14, Núm. 11, pp. 1607-1615

1999

  1. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

    Journal of Clinical Oncology, Vol. 17, Núm. 2, pp. 585-592

1998

  1. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer

    Annals of Oncology, Vol. 9, Núm. 4, pp. 457-459

1997

  1. Mediastinal non-seminomatous germ cell turnouts (MNSGCT) treated with cisplatin-based combination chemotherapy

    Annals of Oncology, Vol. 8, Núm. 6, pp. 555-559

  2. Patient selection in high-dose chemotherapy trials: Relevance in high- risk breast cancer

    Journal of Clinical Oncology, Vol. 15, Núm. 10, pp. 3178-3184

  3. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer

    Seminars in Oncology, Vol. 24, Núm. 6 SUPPL. 19

1996

  1. Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation.

    Journal of the National Cancer Institute